1
|
Abd-Elghany AE, El-Garhy O, Fatease AA, Alamri AH, Abdelkader H. Enhancing Oral Bioavailability of Simvastatin Using Uncoated and Polymer-Coated Solid Lipid Nanoparticles. Pharmaceutics 2024; 16:763. [PMID: 38931885 PMCID: PMC11206705 DOI: 10.3390/pharmaceutics16060763] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2024] [Revised: 06/01/2024] [Accepted: 06/03/2024] [Indexed: 06/28/2024] Open
Abstract
Simvastatin (SVA) is a well-prescribed drug for treating cardiovascular and hypercholesterolemia. Due to the extensive hepatic first-pass metabolism and poor solubility, its oral bioavailability is 5%. Solid lipid nanoparticles (SLNs) and hydrogel-coated SLNs were investigated to overcome the limited bioavailability of SVA. Four different lipids used alone or in combination with two stabilizers were employed to generate 13 SLNs. Two concentrations of chitosan (CS) and alginate (AL) were coating materials. SLNs were studied for particle size, zeta potential, in vitro release, rheology, and bioavailability. The viscosities of both the bare and coated SLNs exhibited shear-thinning behavior. The viscosity of F11 (Chitosan 1%) at 20 and 40 rpm were 424 and 168 cp, respectively. F11 had a particle size of 260.1 ± 3.72 nm with a higher release; the particle size of F11-CS at 1% was 524.3 ± 80.31 nm. In vivo studies illustrated that F11 had the highest plasma concentration when compared with the SVA suspension and coated chitosan (F11 (Chitosan 1%)). Greater bioavailability is measured as (AUC0→24), as compared to uncoated ones. The AUC for F11, F11-CS 1%, and the SVA suspension were 1880.4, 3562.18, and 272 ng·h/mL, respectively. Both bare and coated SLNs exhibited a significantly higher relative bioavailability when compared to that from the control SVA.
Collapse
Affiliation(s)
- Amira E. Abd-Elghany
- Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia 61519, Egypt; (A.E.A.-E.); (O.E.-G.)
| | - Omar El-Garhy
- Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia 61519, Egypt; (A.E.A.-E.); (O.E.-G.)
| | - Adel Al Fatease
- Department of Pharmaceutics, College of Pharmacy, King Khalid University, Abha 62223, Saudi Arabia; (A.A.F.); (A.H.A.)
| | - Ali H. Alamri
- Department of Pharmaceutics, College of Pharmacy, King Khalid University, Abha 62223, Saudi Arabia; (A.A.F.); (A.H.A.)
| | - Hamdy Abdelkader
- Department of Pharmaceutics, College of Pharmacy, King Khalid University, Abha 62223, Saudi Arabia; (A.A.F.); (A.H.A.)
| |
Collapse
|
2
|
Verma S, Paliwal S. Recent Developments and Applications of Biocatalytic and Chemoenzymatic Synthesis for the Generation of Diverse Classes of Drugs. Curr Pharm Biotechnol 2024; 25:448-467. [PMID: 37885105 DOI: 10.2174/0113892010238984231019085154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2022] [Revised: 08/26/2023] [Accepted: 09/19/2023] [Indexed: 10/28/2023]
Abstract
Biocatalytic and chemoenzymatic biosynthesis are powerful methods of organic chemistry that use enzymes to execute selective reactions and allow the efficient production of organic compounds. The advantages of these approaches include high selectivity, mild reaction conditions, and the ability to work with complex substrates. The utilization of chemoenzymatic techniques for the synthesis of complicated compounds has lately increased dramatically in the area of organic chemistry. Biocatalytic technologies and modern synthetic methods are utilized synergistically in a multi-step approach to a target molecule under this paradigm. Chemoenzymatic techniques are promising for simplifying access to essential bioactive compounds because of the remarkable regio- and stereoselectivity of enzymatic transformations and the reaction diversity of modern organic chemistry. Enzyme kits may include ready-to-use, reproducible biocatalysts. Its use opens up new avenues for the synthesis of active therapeutic compounds and aids in drug development by synthesizing active components to construct scaffolds in a targeted and preparative manner. This study summarizes current breakthroughs as well as notable instances of biocatalytic and chemoenzymatic synthesis. To assist organic chemists in the use of enzymes for synthetic applications, it also provides some basic guidelines for selecting the most appropriate enzyme for a targeted reaction while keeping aspects like cofactor requirement, solvent tolerance, use of whole cell or isolated enzymes, and commercial availability in mind.
Collapse
Affiliation(s)
- Swati Verma
- Department of Pharmacy, ITS College of Pharmacy, Muradnagar, Ghaziabad, India
- Department of Pharmacy, Banasthali Vidyapith, Banasthali, 304022, Rajasthan, India
| | - Sarvesh Paliwal
- Department of Pharmacy, Banasthali Vidyapith, Banasthali, 304022, Rajasthan, India
| |
Collapse
|
3
|
Ábrego-García A, Poggi-Varaldo HM, Ponce-Noyola MT, Calva-Calva G, Galíndez-Mayer CJJ, Medina-Mendoza GG, Rinderknecht-Seijas NF. Bioprocessing of Two Crop Residues for Animal Feeding into a High-Yield Lovastatin Feed Supplement. Animals (Basel) 2022; 12:ani12192697. [PMID: 36230438 PMCID: PMC9559462 DOI: 10.3390/ani12192697] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2022] [Revised: 10/01/2022] [Accepted: 10/03/2022] [Indexed: 11/05/2022] Open
Abstract
Simple Summary Lovastatin is a fungal secondary metabolite that can mitigate rumen methane production. This work aimed at evaluating the lovastatin production by solid-state fermentation from selected crop residues and A. terreus strains, considering the post-fermented residues as feed supplements for ruminants. Fermented oat straw by A. terreus CDBB H-194 exhibited the highest lovastatin yield (23.8 mg/g DM fed). GC–MS analysis identified only a couple of compounds from the residues fermented by CDBB H-194 (1,3-dipalmitin trimethylsilyl ether in the fermented oat straw) and stearic acid hydrazide in the fermented wheat bran) that could negatively affect ruminal bacteria and fungi. Abstract This work aimed to evaluate the lovastatin (Lv) production by solid-state fermentation (SSF) from selected crop residues, considering the post-fermented residues as feed supplements for ruminants. The SSF was performed with two substrates (wheat bran and oat straw) and two A. terreus strains (CDBB H-194 and CDBB H-1976). The Lv yield, proximate analysis, and organic compounds by GC–MS in the post-fermented residues were assessed. The combination of the CDBB H-194 strain with oat straw at 16 d of incubation time showed the highest Lv yield (23.8 mg/g DM fed) and the corresponding degradation efficiency of hemicellulose + cellulose was low to moderate (24.1%). The other three treatments showed final Lv concentrations in decreasing order of 9.1, 6.8, and 5.67 mg/g DM fed for the oat straw + CDBB H-1976, wheat bran + CDBB H-194, and wheat bran + CDBB H-1976, respectively. An analysis of variance of the 22 factorial experiment of Lv showed a strong significant interaction between the strain and substrate factors. The kinetic of Lv production adequately fitted a zero-order model in the four treatments. GC–MS analysis identified only a couple of compounds from the residues fermented by A. terreus CDBB H-194 (1,3-dipalmitin trimethylsilyl ether in the fermented oat straw and stearic acid hydrazide in the fermented wheat bran) that could negatively affect ruminal bacteria and fungi. Solid-state fermentation of oat straw with CDBB H-194 deserves further investigation due to its high yield of Lv; low dietary proportions of this post-fermented oat straw could be used as an Lv-carrier supplement for rumen methane mitigation.
Collapse
Affiliation(s)
- Amaury Ábrego-García
- Department of Biotechnology and Bioengineering, CINVESTAV-IPN, P.O. Box 14-740, Mexico City 07000, Mexico
- Environmental Biotechnology and Renewable Energies Group, CINVESTAV-IPN, P.O. Box 14-740, Mexico City 07000, Mexico
| | - Héctor M. Poggi-Varaldo
- Department of Biotechnology and Bioengineering, CINVESTAV-IPN, P.O. Box 14-740, Mexico City 07000, Mexico
- Environmental Biotechnology and Renewable Energies Group, CINVESTAV-IPN, P.O. Box 14-740, Mexico City 07000, Mexico
- Correspondence: ; Tel.: +52-55-57473800 (ext. 4324 & 4306)
| | - M. Teresa Ponce-Noyola
- Department of Biotechnology and Bioengineering, CINVESTAV-IPN, P.O. Box 14-740, Mexico City 07000, Mexico
| | - Graciano Calva-Calva
- Department of Biotechnology and Bioengineering, CINVESTAV-IPN, P.O. Box 14-740, Mexico City 07000, Mexico
| | - Cutberto José Juvencio Galíndez-Mayer
- Departamento de Ingeniería Bioquímica, ENCB, Instituto Politécnico Nacional, Av. Wilfrido Massieu 399, Nueva Industrial Vallejo, Mexico City 07738, Mexico
| | - Gustavo G. Medina-Mendoza
- Department of Biotechnology and Bioengineering, CINVESTAV-IPN, P.O. Box 14-740, Mexico City 07000, Mexico
| | - Noemí F. Rinderknecht-Seijas
- Escuela Superior de Ingeniería Química e Industrias Extractivas, Instituto Politécnico Nacional, Av. Luis Enrique Erro S/N, Nueva Industrial Vallejo, Gustavo A. Madero, Mexico City 07738, Mexico
| |
Collapse
|